Samsung Bioepis Co., Ltd. today announced that PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...

Swiss generics and biosimilars major Sandoz has announced the launch of Pyzchiva (ustekinumab-ttwe) in the USA. From today, ...

As telecom operators face mounting pressure to modernize aging infrastructure while maintaining service continuity, IPLOOK delivers a cost-efficient evolution blueprint that bridges legacy 2G/3G ...

Market Dojo, a leader in eSourcing solutions, has partnered with Focal Point, a pioneer in intake and orchestration, to deliver an integrated platform that streamlines procurement success. A Seamless ...

Monday said that Pyzchiva (ustekinumab-ttwe) is now commercially available to patients across the U.S. Developed by Samsung Bioepis Co., and commercialized by Sandoz, Pyzchiva has been approved by the ...

South Korea’s biggest business group Samsung has sweetened the pot to win a technology talent war by lowering the bar for new ...

TALTZ (ixekizumab), an IL-17A inhibitor by Eli Lilly, has shown strong market growth driven by increasing adoption in psoriasis, psoriatic arthritis, ...